

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: M. Rigdon Lentz

Serial No.: 09/709,045

Art Unit: 1647

Filed: November 10, 2000

Examiner: Lorraine Spector

For: *METHOD AND SYSTEM TO REMOVE CYTOKINE INHIBITOR IN PATIENTS*

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Sir:

Pursuant to 37 C.F.R. §1.56 and 37 C.F.R. §1.97, Applicant submits a Supplemental Information Disclosure Statement, including four (4) pages of Form PTO-1449, and copies of twenty-eight (28) documents cited therein.

Pursuant to the waiver in the notice entitled "Information Disclosure Statements May Be Filed Without Copies of U.S. Patents and Published Applications in Patent Applications Filed After June 30, 2003" published on August 5, 2003 in 1273 OG 55, copies of the U.S. Patent Applications are not enclosed.

The requirement for a concise explanation of the relevance of the foreign language document (marked with an asterisk (\*) in the list below) under 37 C.F.R. § 1.98(a)(3) is satisfied by the English language abstract that appears on page 2 of the enclosed, full-length Russian Patent.

U.S.S.N.: 09/709,045  
Filed: November 10, 2000  
SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT

It is believed that no fee is required with this submission. However, should an additional fee be required, the Commissioner is hereby authorized to charge any required fees to Deposit Account No. 50-3129.

### U.S. Patent Applications

<u>Number</u>	<u>Filing Date</u>	<u>Patentee</u>	<u>Class/Subclass</u>
2002/0114728	08-22-2002	Kulish, et al.	422/22
2003/0129130	07-10-2003	Guire, et al.	424/1.11

### Foreign Documents

<u>Number</u>	<u>Publication Date</u>	<u>Patentee</u>	<u>Country</u>
WO 03/056896	07-17-2003	Molecular Staging Inc.	PCT
*2 130 069 (w/ Engl. Abstract)	05-10-1999	Inst Ehlemento- organicheskikh S	RU

### Publications

ADOLF and FRÜHBEIS, "Monoclonal antibodies to soluble human TNF receptor (TNF binding protein) enhance its ability to block TNF toxicity.", *Cytokine*, 4(3):180-184 (1992).

BJORNBERG, et al., "Mechanisms involved in the processing of the p55 and the p75 tumor necrosis factor (TNF) receptors to soluble receptor forms", *Lymphokine Cytokine Res.*, 13(3):203-11 (1994).

CSEHI, et al., "Tumor necrosis factor (TNF) interferes with insulin signaling through the p55 TNF receptor death domain", *Biochem Biophys Res Commun*, 329(1):397-405 (2005).

FENG, "Regulatory roles and molecular signaling of TNF family members in osteoclasts", *Gene*, 350(1):1-13 (2005).

GADDUCCI, et al., "Serum levels of tumor necrosis factor (TNF), soluble receptors for TNF (55- and 75-kDa sTNFr), and soluble CD14 (sCD14) in epithelial ovarian cancer", *Gynecol Oncol*, 58(2):184-8 (1995).

GRELL, et al., "The type 1 receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis factor", *Proc Natl Acad Sci U S A.*, 95(2):570-5 (1998).

GROSEN, et al., "Measurement of the soluble membrane receptors for tumor necrosis factor and lymphotoxin in the sera of patients with gynecologic malignancy", *Gynecol Oncol*, 50(1):68-77 (1993).

HASEGAWA, et al., "Increased soluble tumor necrosis factor receptor levels in the serum of elderly people", *Gerontology*, 46(4):185-8 (2000).

HOLTMANN, et al., "The emerging distinct role of TNF-receptor 2 (p80) signaling in chronic inflammatory disorders", *Arch Immunol Ther Exp (Warsz)*, 50(4):279-88 (2002).

JABLONSKA, et al., "Tumor necrosis factor-alpha and soluble tumor necrosis factor receptors in the culture supernatants of polymorphonuclear cells and peripheral blood mononuclear cells from cancer patients", *Eur Cytokine Netw*, 9(2):155-9 (1998).

LIU, et al., "Molecular mechanism of TNF signaling and beyond", *Cell Res*, 15(1):24-7 (2005).

MACALLAN, et al., "Development of a novel TNF alpha ligand-receptor binding assay for screening NATCHEM Libraries", *J Recept Signal Transduct Res*, 17(1-3):521-9 (1997).

MAIER, et al., "Physiological levels of pro- and anti-inflammatory mediators in cerebrospinal fluid and plasma: a normative study", *J Neurotrauma*, 22(7):822-35 (2005).

MUC-WIERZGON, et al., "Circadian fluctuations of melatonin, tumor necrosis factor-alpha and its soluble receptors in the circulation of patients with advanced gastrointestinal cancer", *J Exp Clin Cancer Res*, 22(2):171-8 (2003).

NOPHAR, et al., "Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type I TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor", *EMBO J*, 9(10):3269-78 (1990).

ONSRUD, et al., "Comparison between soluble tumor necrosis factor receptors and CA125 in peritoneal fluids as a marker for epithelial ovarian cancer", *Gynecol Oncol*, 57(2):183-7 (1995).

ONSRUD, et al., "Soluble tumor necrosis factor receptors and CA 125 in serum as markers for epithelial ovarian cancer", *Tumour Biol*, 17(2):90-6 (1996).

RZYMSKI, et al., "Serum tumor necrosis factor alpha receptors p55/p75 ratio and ovarian cancer detection", *J Gynaecol Obstet*, 88(3):292-8 (2005).

SERWIN, et al., "[Soluble tumor-necrosis-factor-alpha receptor type-1 as a marker of activity of psoriasis vulgaris and effects of its treatment]", *Przegl Lek*, 62(2):95-7 (2005).

SERWIN, et al., "Soluble tumor necrosis factor alpha receptor type 1 in psoriasis patients treated with narrowband ultraviolet B" *Photodermatol Photoimmunol Photomed*, 21(4):210-1 (2005).

SHAI, et al., "A prospective study of soluble tumor necrosis factor-alpha receptor II (sTNF-RII) and risk of coronary heart disease among women with type 2 diabetes", *Diabetes Care*, 28(6):1376-82 (2005).

SUKHIKH, et al., "Disorders in cytokine gene expression in endometrial hyperplasia and effect of hormone therapy", *Bull Exp Biol Med.*, 139(2):235-7 (2005).

TESAROVA, et al., "Soluble TNF and IL-2 receptors in patients with breast cancer", *Med Sci Monit*, 6(4):661-7 (2000).

THEISS, et al., "Tumor Necrosis Factor (TNF) {alpha} Increases Collagen Accumulation and Proliferation in Intestinal Myofibroblasts via TNF Receptor 2", *J Biol Chem*, 280(43):36099-109 (2005).

WAJANT, et al., "Tumor necrosis factor signaling", *Cell Death Differ*, 10(1):45-65 (2003).

WOZEL, "[Etanercept An effective TNF alpha-antagonist in the treatment of psoriatic arthritis and chronic plaque psoriasis.]" *Hautarzt*, 56(9):819-830 (2005).

U.S.S.N.: 09/709,045  
Filed: November 10, 2000  
SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT

### Remarks

This statement should not be interpreted as a representation that an exhaustive search has been conducted or that no better art exists. Moreover, Applicant invites the Examiner to make an independent evaluation of the cited art to determine its relevance to the subject matter of the present application. Applicant is of the opinion that his claims patentably distinguish over the art referred to herein, either alone or in combination.

Respectfully submitted,

/ Patrea L. Pabst /

---

Patrea L. Pabst  
Reg. No. 31,284

Dated: September 4, 2009

PABST PATENT GROUP LLP  
1545 Peachtree Street NE  
Suite 320  
Atlanta, GA 30309  
(404) 879-2151 (Telephone)  
(404) 879-2160 (Fax)